A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTIPLE-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BIIB104 IN SUBJECTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS)", PROTOCOL NO. 263CS201
Principal Investigator(s)
Velligan, Dawn I
Funded by
BIOGEN, INC.
Research Start Date
Status
Active